Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer

BACKGROUND: ALK‐tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK‐positive non‐small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Jin, Chen, Hua‐Jun, Zhang, Xu‐Chao, Su, Jian, Zhou, Qing, Tu, Hai‐Yan, Wang, Zhen, Wang, Bin‐Chao, Zhong, Wen‐Zhao, Yang, Xue‐Ning, Chen, Zhi‐Hong, Ding, Yan, Wu, Xue, Wang, Mei, Fu, Jian‐Gang, Yang, Zhenfan, Zhang, Xian, Shao, Yang W., Wu, Yi‐Long, Yang, Jin‐Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119621/
https://www.ncbi.nlm.nih.gov/pubmed/29978950
http://dx.doi.org/10.1111/1759-7714.12791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119621/
https://www.ncbi.nlm.nih.gov/pubmed/29978950
http://dx.doi.org/10.1111/1759-7714.12791

Ejemplares similares